Nephrology

Chronic Kidney Disease Linked to Uncontrolled Blood Pressure

Publish Date April 3, 2020

Second study shows ambulatory BP patterns not tied to cognitive impairment or frailty in CKD patients

Dapagliflozin CKD Trial Stopped Early Due to “Overwhelming Efficacy”

Publish Date April 2, 2020

The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.

Dialysis Industry Unites In Wake of COVID-19 Pandemic

Publish Date April 1, 2020

DaVita Inc. and Fresenius Medical Care North America (FMCNA) jointly announced they are collaborating in response to the COVID-19 pandemic to offer isolation capacity for dialysis patients who are or may be infected with the novel coronavirus that causes the disease. The companies, which are the largest providers of dialysis in the United States, also…

BP Load No Aid to Prognosis in Pediatric Chronic Kidney Disease

Publish Date April 1, 2020

But high average blood pressure on 24-hour test strongly predicts child’s cardiac, kidney disease risk.

COVID-19 Surfaces in a US Hemodialysis Patient

Publish Date March 25, 2020

Physicians at the University of California Irvine describe an unusual presentation of the novel coronavirus illness in a 56-year-old man. The case is believed to be among the first COVID-19 cases in the United States.

NKF Urges Dialysis Patients Not to Stop Treatments

Publish Date March 19, 2020

The National Kidney Foundation issued a statement today urging patients on dialysis to continue undergoing treatments during the COVID-19 pandemic. “It is extremely important for kidney patients to continue with their regularly scheduled dialysis treatments and take extra precautions when visiting the facilities to best protect their health,” said Joseph Vassalotti, MD, Chief Medical Officer for NKF. “Skipping…

Glecaprevir/Pibrentasvir Effective for Chronic HCV Infection With CKD

Publish Date March 18, 2020

Glecaprevir/pibrentasvir for 8 to 12 weeks is an effective and well-tolerated treatment for patients with chronic hepatitis C virus and chronic kidney disease stage 4 or 5.

Empagliflozin Fast-Tracked for Chronic Kidney Disease Treatment

Publish Date March 16, 2020

The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.

Talzenna Dosing Updated to Include Patients With Severe Renal Impairment

Publish Date March 12, 2020

The prescribing information for Talzenna (talazoparib; Pfizer) has been updated to include recommendations for patients with severe renal impairment.

CDC Updates Guidance on Evaluating, Testing for COVID-19 as More Tests Become Available

Publish Date March 11, 2020

The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.